Biologics in the treatment of Severe Asthma
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.
| Hoofdauteur: | |
|---|---|
| Andere auteurs: | |
| Formaat: | Thesis |
| Taal: | en_US |
| Gepubliceerd in: |
Brac University
2022
|
| Onderwerpen: | |
| Online toegang: | http://hdl.handle.net/10361/17597 |
| id |
10361-17597 |
|---|---|
| record_format |
dspace |
| spelling |
10361-175972022-11-21T21:01:45Z Biologics in the treatment of Severe Asthma Hassan, Shah Musallin Kabir, Dr. Eva Rahman Department of Pharmacy, Brac University Asthma Biologics Eosinophil Phenotype Omalizumab Severe asthma Respiratory allergy Antiasthmatic agents This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. Cataloged from PDF version of thesis report. Includes bibliographical references (pages 26-32). At present, asthma is one of the major chronic respiratory diseases that distorts the daily life of nearly 300 million people around the globe and almost 5–10% of these people experience severe or uncontrolled asthma. Asthma is a condition in which the airways undergo chronic inflammation resulting in wheezing and difficulty in breathing. It is predominantly triggered due to an irritant or an allergen, virus exposure, exercise and emotional stress. Contemporary treatment of asthma includes inhaled corticosteroid (ICS) with montelukast or theophylline as additional controllers and oral corticosteroids and inhaled long-acting beta 2 agonists (LABA) are administered in case of insufficient control of symptoms. The advent of biologics became pivotal since the conventional treatment alternatives were ineffective in the control of severe asthma. Omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab are the biologics that have been implemented successfully in treating severe asthma patients. This enabled patient specific, safe and effective treatment for asthmatics. Shah Musallin Hassan B. Pharmacy 2022-11-21T05:38:55Z 2022-11-21T05:38:55Z 2022 2022-04 Thesis ID: 18146014 http://hdl.handle.net/10361/17597 en_US Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 32 Pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
en_US |
| topic |
Asthma Biologics Eosinophil Phenotype Omalizumab Severe asthma Respiratory allergy Antiasthmatic agents |
| spellingShingle |
Asthma Biologics Eosinophil Phenotype Omalizumab Severe asthma Respiratory allergy Antiasthmatic agents Hassan, Shah Musallin Biologics in the treatment of Severe Asthma |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. |
| author2 |
Kabir, Dr. Eva Rahman |
| author_facet |
Kabir, Dr. Eva Rahman Hassan, Shah Musallin |
| format |
Thesis |
| author |
Hassan, Shah Musallin |
| author_sort |
Hassan, Shah Musallin |
| title |
Biologics in the treatment of Severe Asthma |
| title_short |
Biologics in the treatment of Severe Asthma |
| title_full |
Biologics in the treatment of Severe Asthma |
| title_fullStr |
Biologics in the treatment of Severe Asthma |
| title_full_unstemmed |
Biologics in the treatment of Severe Asthma |
| title_sort |
biologics in the treatment of severe asthma |
| publisher |
Brac University |
| publishDate |
2022 |
| url |
http://hdl.handle.net/10361/17597 |
| work_keys_str_mv |
AT hassanshahmusallin biologicsinthetreatmentofsevereasthma |
| _version_ |
1814308477082796032 |